【摘 要】
：
Anticoagulants and anti-platelet agents are simultaneously administrated in clinical practice(i.e.percutaneous coronary intervention),which cause significant risk of systemic bleeding.Targeted deliver
【机 构】
：
Department of Molecular and Cellular Pharmacology,Stale Key Laboratory of Natural and Biomimetic Dru
【出 处】
：
第八届国际分子模拟与信息技术应用学术会议
论文部分内容阅读
Anticoagulants and anti-platelet agents are simultaneously administrated in clinical practice(i.e.percutaneous coronary intervention),which cause significant risk of systemic bleeding.Targeted delivery of anticoagulants to the activated platelets at sites of vascular injuries may condense the sitespecific anticoagulant effect and reduce the hemorrhage side effects in uninjured vessels.To this end,we prepared three ancylostoma caninum anticoagulant peptide 5(AcAP5)variants NR1,NR2 and NR3 engineered with a platelet-binding Arg-Gly-Asp(RGD)motif and evaluated their anti-Factor Xa(FXa)and platelet-binding effects.These RGD-containing AcAP5 variants were capable of interacting with platelet receptor αIIbβ3 as shown in computational analysis.All variants,especially NR2 and NR3,retained entirely the anti-FXa function of parent AcAP5.Moreover,they prevented the formation of occlusive thrombi in rat carotid artery injury model,suggesting that they inhibit platelet aggregation in vivo.Further functional investigation of NR3 demonstrated that NR3 inhibited platelet aggregation in vitro and FXa activity in vivo,and prolonged the coagulation time,all in a dose-dependent manner.Through flaw cytometry assay,we confirmed the binding of NR3 to αIIbβ3 receptor.In mouse model of carotid artery endothelium injury,NR3-treated mice showed less tail bleeding time than AcAP5-treated mice,and aspirin plus NR3 treatment exhibited moderate reduction of blood loss compared with aspirin plus AcAP5 treatment.These results indicate the feasibility to engineer a novel FXa inhibitor specifically targeting the activated platelets,which centralizes its anticoagulation efficacy in the injured vascular endothelium and reduces the risk of systemic bleeding.
其他文献
Background: Trichinellosis is a re-emerging infectious disease,caused by Trichinella spp.Cathepsin F belongs to cysteine protease that is a major virulence factor for parasitic helminths,and it may be
Protein electrospray ionization(ESI)mass spectrometry(MS)-based techniques are widely used to provide insight into structural proteomics under the assumption that non-covalent protein complexes being
The interaction between barrier-to-autointegration factor dimer(BAF2)and LEM domain of emerin(EmLEM was studied by molecular simulation methods.Nonspecific fragment of double-strand DNA molecule was d
Histone deacetylase inhibitors(HDIs)are an increasingly important class of cancer-targeting agent.Two kinds of small molecule histone deacetylase inhibitors,mainly employing the motifs of the two know
The connection between inflammation and tumourigenesis has been well established.However,the detailed molecular mechanism underlying inflammation-associated tumourigenesis remains unknown because this
Traditional Chinese medicine(TCM)is a multi-component and multi-target agent and could treat complex diseases in a holistic way,especially infection diseases.However,the underlying pharmacology remain
Metronidazole-sulfonamide derivatives 4a-4l,a new class of human carbonic anhydrase inhibitors(hCA),were designed,synthesized,isolated,and evaluated for their ability to inhibit the enzymatic activity
The aim of this study was to investigate the angiogenic effects of curcumin on an ischemia and lung cancer model.To induce ischemia combined with lung cancer models,unilateral femoral arteries of C57B
Background: Quantitative description of dose-response of a drug for complex systems is essential fortreatment of diseases and drug discovery.Given the growth of large-scale biological data obtained by
Cytochrome P450(CYP)17A1 is a dual-function monooxygenase with a critical role in the synthesis or many human steroid hormones The enzyme is an important target for Lrealment of breast and prostate ca